<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362713</url>
  </required_header>
  <id_info>
    <org_study_id>CA184-027</org_study_id>
    <nct_id>NCT00362713</nct_id>
    <nct_alias>NCT00462930</nct_alias>
  </id_info>
  <brief_title>Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection</brief_title>
  <official_title>A Phase 1b Safety and Dose-Assessment Study of Neoadjuvant Ipilimumab Monotherapy in Patients With Urothelial Carcinoma Undergoing Surgical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn if ipilimumab can be given safely at two different&#xD;
      doses given to patients with urothelial cancer who are going to have surgery as part of their&#xD;
      treatment. The immunological effectiveness of ipilimumab will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of two dose levels of ipilimumab, given prior to surgery, in this patient population.</measure>
    <time_frame>assessed throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate anti-cancer immunological activity in blood and tissue samples compared to pre-treatment or control samples.</measure>
    <time_frame>assessed throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg or 10 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Intravenous Solution, Intravenous, One dose every 3 weeks for four weeks, followed through Week 24</description>
    <arm_group_label>A</arm_group_label>
    <other_name>BMS-734016</other_name>
    <other_name>MDX-010</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously untreated urothelial cancer requiring surgery for treatment&#xD;
&#xD;
          -  Ineligible for chemotherapy&#xD;
&#xD;
          -  Adequate hematologic, kidney and liver function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sexually active and fertile individuals or partners of these individuals who are&#xD;
             unwilling or unable to use an acceptable method of birth control for the entire trial&#xD;
             and up to 4 weeks after the study&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Women with a positive pregnancy test on enrollment prior to study drug administration&#xD;
&#xD;
          -  Prior treatment with ipilimumab or other anti-CTLA4 antibody, or a CD137 agonist&#xD;
&#xD;
          -  Concurrent malignancy, with the exception of adequately treated and cured basal or&#xD;
             squamous cell skin cancer, or carcinoma in situ of the cervix (previous malignancy&#xD;
             without evidence of disease for 5 years will also be allowed to enter trial)&#xD;
&#xD;
          -  Autoimmune disease: subjects with a documented history of inflammatory bowel disease&#xD;
             (including Crohn's disease and ulcerative colitis) are excluded from this study as are&#xD;
             patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic&#xD;
             progressive sclerosis [scleroderma], Systemic Lupus Erythematosus, autoimmune&#xD;
             vasculitis [e.g., Wegener's Granulomatosis]). Subjects with motor neuropathy&#xD;
             considered of autoimmune origin (e.g., Guillain-Barre Syndrome) are excluded from this&#xD;
             study&#xD;
&#xD;
          -  Patients deemed ineligible for surgery&#xD;
&#xD;
          -  Any non-oncology vaccine therapy used for prevention of infectious diseased in the&#xD;
             past month&#xD;
&#xD;
          -  Concomitant therapy with any of the following: IL-2, interferon or other non-study&#xD;
             immunotherapy regimens, chemotherapy; immunosuppressive agents; other investigation&#xD;
             therapies; or chronic use of systemic corticosteroids (used in the management of&#xD;
             cancer or non-cancer related illnesses)&#xD;
&#xD;
          -  Prior radiation therapy for urothelial cancer&#xD;
&#xD;
          -  Positive screening tests for or any prior history of HIV, Hepatitis B or Hepatitis C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University Of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>August 7, 2006</study_first_submitted>
  <study_first_submitted_qc>August 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2006</study_first_posted>
  <last_update_submitted>September 29, 2016</last_update_submitted>
  <last_update_submitted_qc>September 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

